EpiSwitch CiRT’s Post

📢 Breaking News! Exeliom is proud to announce the launch of three phase II clinical trials in immuno-oncology, marking a significant milestone in the fight against cancer. Our lead candidate, EXL01, will be evaluated in gastric cancer, NSCLC, and hepatocellular carcinoma, in collaboration GERCOR, CHU de Lille, and Centre Eugène Marquis of Rennes. EXL01, the first-ever single-strain Live Biotherapeutic Product (LBP) utilizing Faecalibacterium prausnitzii, holds promise as an adjuvant to immune checkpoint inhibitors, potentially revolutionizing cancer treatment outcomes. These trials aim to address the unmet medical needs of patients with poor prognosis, with results expected by the end of 2026. Positive outcomes could pave the way for phase III studies. 🔗 https://lnkd.in/e26ksZ7q #ImmunoOncology #CancerResearch #ClinicalTrials #Immunotherapy #Inflammation

Heading to #ASCO24? Join Andrea Necchi, MD, Matthew Galsky, MD, Shilpa Gupta, MD, and Michiel S. van der Heijden, MD, PhD on Friday, May 31 at 6:30 PM CDT / 7:30 PM EDT in person or online for a Candid Conversations on Urothelial Cancer #MedEd event. Produced with the Bladder Cancer Advocacy Network, This event will provide insight on how immune checkpoint inhibitors, fibroblast growth factor receptor (#FGFR) inhibitors, and antibody-drug conjugates (#ADCs), approved or being studied as monotherapy or in combination with other agents, along with novel approaches to drug delivery, can be used in patients with advanced or metastatic disease and increasingly in earlier stages of disease. 🔗 Register now: https://lnkd.in/e59Bmk3S #BladderCancer #Oncology #MedEd #ASCO24

Curious about how the Onco-PDO® test works? Check out our infographic to see the step-by-step workflow of this revolutionary cancer treatment approach! Here's a brief overview: Tumor cells are cultured into mini-organs in a 3D structure, known as Patient-Derived Organoids (PDOs). The drugs selected by physicians are then tested on the patient's individual mini-organs (PDOs) in the lab. Each treatment's response is analyzed, and a report is delivered within a clinically relevant timeframe, allowing doctors to make more informed decisions for personalized cancer treatment. Contact us to learn more about the Onco-PDO® test. #PrecisionOncology #Livingsciences #cancertreatment #CancerCare #OncoPDO #PersonalizedMedicine #InnovativeTreatment #BetterOutcomes Follow us on Facebook at https://lnkd.in/gtZqUqGb and Instagram at https://lnkd.in/gKJyHuvh to gain access to our novel approach to personalizing cancer; the Onco-PDO® test that will reshape the landscape of oncology.

#ESMO 2024 will have two practice-changing trials of #Keytruda (#Pembrolizumab) presented within Presidential Symposium. We'll see first time OS results from Phase III Keynote-522 trial of #Keytruda in combination with chemotherapy as neoadjuvant treatment and then continuing as single agent adjuvant in #TNBC patients with high-risk early-stage disease. Also, OS from the Phase III Keynote-A18 trial evaluating #Keytruda in combination with concurrent #chemoradiotherapy (#CRT) as treatment for patients with high-risk locally advanced #cervical cancer. Amazing success for Merck Women's cancer team and testament to outstanding leadership of immunooncology expert Gursel Aktan and her absolute commitment to cancer patients! Congratulations! https://lnkd.in/eV_xBC3m #immunooncology #ESMO #practice changing #Keynote #PhIII #OS #PD-1 #neoadjuvant #adjuvant #

Phase 1 PROCEADE-CRC-01 Trial: M9140 showed promise in treating advanced colorectal cancer, helping patients live longer without their disease worsening. The novel anti-CEACAM5 antibody-drug conjugate M9140 is showing early promise in the fight against metastatic colorectal cancer (CRC). CEACAM5, a cell surface protein, is found in over 90% of CRC patients, making it a critical target for new therapies. These results highlight the potential of M9140 to offer new hope for patients with advanced CRC. At VieCure, we prioritize improving patient outcomes through precision oncology. By implementing guideline-based molecular testing, we can accurately identify the right patients for the right treatments, enhancing the effectiveness of cancer care. This approach ensures that oncologists have the information they need to make informed decisions, ultimately leading to better patient outcomes. #VieCure #Oncology https://lnkd.in/gV7AVAQ5

NEW: Highlights from #SABCS2023: #novelagents and insights on #HER2 dynamics in #breastcancer 🇺🇸 🎥 Kevin Kalinsky, MD, MS, from the Winship Cancer Institute of Emory University, discusses exciting posters presented during the spotlight session at the San Antonio Breast Cancer Symposium (SABCS) 2023 💡The main focus is on new agents, including two #bispecificantibodies and a TROP-2 #antibodydrugconjugate (ADC) 💡A real-world analysis, RELIEVE, underscores the importance of #HER2 dynamics, revealing potential differences in outcomes for patients with #HER2-low #primarytumors and #metastatic tumors 💡The discussion emphasizes considerations about #toxicities, responses, and the optimal measurement of targets, questioning whether #targetedtherapies induce bystander effects that render assays less critical Take a look 👉 https://lnkd.in/ethirU9d Check out our #SABCS page for all the latest coverage 👉 https://lnkd.in/eYrYkh5C #SABCS23 #BreastCancer #BCsm #breastcancerawareness  American Association for Cancer Research

In a recent study, researchers investigated the efficacy of sequential antibody-drug conjugate (ADC) therapy in metastatic breast cancer, specifically focusing on the use of sacituzumab govitecan (SG) and trastuzumab deruxtecan (TDXd). Modest clinical activity of both SG and TDXd when used as second-line ADC therapy (ADC2) in heavily pre-treated patients. The study highlighted that the treatment line at the time of ADC2 significantly influenced PFS, with later treatment lines correlating with shorter PFS. Moreover, the study emphasized the need for further research to explore the potential implications of payload cross-resistance, which could potentially undermine the benefits of sequential ADC therapy in metastatic breast cancer. This call for additional studies underscores the complexity of treatment strategies in advanced breast cancer and the importance of optimizing therapeutic approaches to improve patient outcomes. Read More https://lnkd.in/dzNWySZv #BreastCancerResearch #ADCTherapy #RealWorldOutcomes #PatientOutcomes #CancerTreatment

#DidYouKnow Oesophageal Cancer (OC) is the 11th most diagnosed cancer and the 7th leading cause of cancer mortality in the world? The overall five-year survival rate for OC is about 20%, which can be improved with early detection. Oesophageal cancer cases are projected to increase significantly, potentially surpassing 923,000 new cases annually by 2050. Since 2019, the biotech and biopharma industry initiated over 1,500 oesophageal cancer trials. You can discover key insights into the current state and the latest advancements in OC research through the in-depth disease analysis provided in Novotech’s report, available for free download via this link: https://lnkd.in/dumy9St7 #OesophagealCancer #MedicalAdvancements #Novotech

This morning, we published a press release announcing the encouraging key conclusions for the updated survival analysis from our Phase 2 C-02 trial in advanced cervical cancer. The analysis highlights the extended benefit beyond what would be expected based on historical data testing atezolizumab (Tecentriq®) as monotherapy.   🌟Key highlights:🌟   *The latest data analysis closely mirrors our previous findings, now with a minimum observation period of 24 months for the remaining patients, providing a more robust basis compared to the earlier 12-month timeframe. *The promising outcomes from the C-02 trial support the accelerated development pathway for VB10.16. This includes moving forward with the anticipated pivotal trial in the U.S., C-04, focused on recurrent or metastatic cervical cancer. *Encouraged by these results, we're not just limiting ourselves to cervical cancer. Plans and activities are in motion to expand the use of VB10.16 into earlier treatment stages and to explore its potential in battling head and neck cancers.   🔗 To dive deeper into these groundbreaking findings, read our press release here https://lnkd.in/eGpPHxkr.    Our journey towards redefining cancer treatment continues, and today's update marks a significant milestone in our pursuit. Stay connected with us as we advance towards making a substantial difference in the lives of those affected by cancer.   #CancerResearch #ClinicalTrials #Innovation #CervicalCancer #Oncology

PD1 and PDL1 inhibitors (in short, PDx) have changed cancer care since the approval of pembrolizumab for melanoma in 2014. The field has expanded since however the progress many patients are not responding to the treatment due to resistance. This overview provided by the Cancer Research Institute (CRI) describes the PDx trials and the emerging terms on the exclusion/inclusion of patients’ resistance. PDx continue to be the primary target of cancer immunotherapy. However, the occurrence of primary and acquired resistance to PDx is driving the development of more sophisticated combination therapy strategies, as well as the exploration of new IO targets in different immune cells. This study concludes that in 2022 the PDx clinical trial testing reduced across phase I to III, pointing to the heterogeneity of clinical strategy based on tumour type. Whereas PDx mAbs still dominate most of the field, PDx bispecific antibodies are gaining ground, and combinations of multiple agents are steadily displacing strategies such as dual combinations with chemotherapy or radiotherapy. Original Nature article link:  https://lnkd.in/gKTu9nai  #PDx #PD-L1 #Cancer #Trials #Immunotherapies #IO